Alexandria Real Estate Equities
ARE
$115.69
Share price
-0.70%
Change (1 day)
-6.85%
Change (1 year)
Categories
Alexandria Real Estate Equities, Inc. is a real estate investment trust that invests in office buildings and laboratories.
Revenue for Alexandria Real Estate Equities (ARE)
Revenue in 2023 (TTM): $2.89 B
According to Alexandria Real Estate Equities 's latest financial reports the company's current revenue (TTM) is $2.89 B. In 2022 the company made a revenue of $2.59 B an increase over the years 2021 revenue that were of $2.11 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alexandria Real Estate Equities from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $2.89 B | 11.85% |
| 2022 | $2.59 B | 22.44% |
| 2021 | $2.11 B | 12.34% |
| 2020 | $1.88 B | 23.03% |
| 2019 | $1.53 B | 15.36% |
| 2018 | $1.32 B | 17.67% |
| 2017 | $1.12 B | 25.64% |
| 2016 | $0.89 B | 9.56% |
| 2015 | $0.81 B | 13.76% |
| 2014 | $0.72 B | 16.18% |
| 2013 | $0.62 B | 3.23% |
| 2012 | $0.60 B | 20.35% |
| 2011 | $0.49 B | 8.69% |
| 2010 | $0.45 B | 17.94% |
| 2009 | $0.38 B | 4.13% |
| 2008 | $0.37 B | 18.53% |
| 2007 | $0.31 B | 29.07% |
| 2006 | $0.24 B | 27.74% |
| 2005 | $0.19 B | 23.82% |
| 2004 | $0.15 B | 16.31% |
| 2003 | $0.13 B | 13.39% |
| 2002 | $0.11 B | 18.74% |
| 2001 | $98.66 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $58.49 B | 1,918.15% | 🇺🇸 USA |
 Eli Lilly LLY | $34.12 B | 1,077.28% | 🇺🇸 USA |
 Amgen AMGN | $28.19 B | 872.56% | 🇺🇸 USA |
 Gilead Sciences GILD | $27.11 B | 835.47% | 🇺🇸 USA |
 Illumina ILMN | $4.50 B | 55.39% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $45.00 B | 1,452.71% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $1.82 B | -36.92% | 🇺🇸 USA |